StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) stock

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.45−0.17 (-3.02%)

Close on Nov 20, 2026Market cap $136.25KP/E –Yield –

AgomAb Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

No free cash flow figures for AgomAb Therapeutics

AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More AgomAb Therapeutics figures

See a number that looks wrong?